Delving into the Latest Updates on GB005, Inc. with Synapse

概览

关联

1

项与 GB005, Inc. 相关的药物

GB-5121

靶点

BTK

作用机制

BTK抑制剂

在研机构-

原研机构

Gossamer Bio, Inc.

在研适应症-

非在研适应症

原发性中枢神经系统淋巴瘤 [+2]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

1

项与 GB005, Inc. 相关的临床试验

NCT05242146 / Terminated临床1期

A Phase 1b/2, Open-label Dose Escalation With Expansion Study of GB5121 in Adult Patients With Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma, With a Phase 2 Open-label Single Dose Level Study of GB5121 in Adult Patients With Relapsed/ Refractory Primary Central Nervous System Lymphoma

The STAR CNS trial is a 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or optimal biological dose, determine the recommended phase 2 dose, preliminary anti-tumor activity and efficacy of the recommended phase 2 dose of GB5121.

开始日期2022-05-24

申办/合作机构

GB005, Inc.

100 项与 GB005, Inc. 相关的临床结果

登录后查看更多信息

0 项与 GB005, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 GB005, Inc. 相关的药物交易

登录后查看更多信息

100 项与 GB005, Inc. 相关的转化医学

登录后查看更多信息